These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37075981)

  • 1. Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis.
    Neighbors M; Li Q; Zhu SJ; Liu J; Wong WR; Jia G; Sandoval W; Tew GW
    J Lipid Res; 2023 Jun; 64(6):100375. PubMed ID: 37075981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.
    Li Q; Wong W; Birnberg A; Chakrabarti A; Yang X; Choy DF; Olsson J; Verschueren E; Neighbors M; Sandoval W; Rosenberger CM; Grimbaldeston MA; Tew GW
    BMC Pulm Med; 2021 Sep; 21(1):301. PubMed ID: 34556083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
    Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
    Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics.
    Yan F; Wen Z; Wang R; Luo W; Du Y; Wang W; Chen X
    BMC Pulm Med; 2017 Dec; 17(1):174. PubMed ID: 29212488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis.
    Montesi SB; Mathai SK; Brenner LN; Gorshkova IA; Berdyshev EV; Tager AM; Shea BS
    BMC Pulm Med; 2014 Jan; 14():5. PubMed ID: 24468008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiopathic pulmonary fibrosis.
    Tanaka T; Koyama K; Takahashi N; Morito K; Ali H; Azuma M; Kagawa K; Kawano H; Has RY; Aihara M; Nishioka Y
    J Med Invest; 2022; 69(3.4):196-203. PubMed ID: 36244770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway.
    Nakamura Y; Shimizu Y
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease.
    Ahmad S; Orellana A; Kohler I; Frölich L; de Rojas I; Gil S; Boada M; Hernández I; Hausner L; Bakker MHM; Cabrera-Socorro A; Amin N; Ramírez A; Ruiz A; Hankemeier T; Van Duijn CM
    Alzheimers Res Ther; 2020 Oct; 12(1):124. PubMed ID: 33008436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPA
    Decato BE; Leeming DJ; Sand JMB; Fischer A; Du S; Palmer SM; Karsdal M; Luo Y; Minnich A
    Respir Res; 2022 Mar; 23(1):61. PubMed ID: 35303880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA
    Corte TJ; Lancaster L; Swigris JJ; Maher TM; Goldin JG; Palmer SM; Suda T; Ogura T; Minnich A; Zhan X; Tirucherai GS; Elpers B; Xiao H; Watanabe H; Smith RA; Charles ED; Fischer A
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34969771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis.
    Uehara M; Enomoto N; Mikamo M; Oyama Y; Kono M; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respir Med; 2016 May; 114():18-26. PubMed ID: 27109807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
    Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
    Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CT
    O'Callaghan M; Duignan J; Tarling EJ; Waters DK; McStay M; O'Carroll O; Bridges JP; Redente EF; Franciosi AN; McGrath EE; Butler MW; Dodd JD; Fabre A; Murphy DJ; Keane MP; McCarthy C
    Respirology; 2023 Nov; 28(11):1043-1052. PubMed ID: 37642207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis.
    Gui X; Qiu X; Tian Y; Xie M; Li H; Gao Y; Zhuang Y; Cao M; Ding H; Ding J; Zhang Y; Cai H
    Int Immunopharmacol; 2019 May; 70():208-215. PubMed ID: 30851700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in accurate quantitation of lysophosphatidic acids in human biofluids.
    Onorato JM; Shipkova P; Minnich A; Aubry AF; Easter J; Tymiak A
    J Lipid Res; 2014 Aug; 55(8):1784-96. PubMed ID: 24872406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis.
    Matsuzawa Y; Kawashima T; Kuwabara R; Hayakawa S; Irie T; Yoshida T; Rikitake H; Wakabayashi T; Okada N; Kawashima K; Suzuki Y; Shirai K
    Pulm Pharmacol Ther; 2015 Jun; 32():1-6. PubMed ID: 25862941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis.
    Nyilas S; Schreder T; Singer F; Poellinger A; Geiser TK; Latzin P; Funke M
    Respirology; 2018 Aug; 23(8):764-770. PubMed ID: 29573509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF).
    Nambiar S; Clynick B; How BS; King A; Walters EH; Goh NS; Corte TJ; Trengove R; Tan D; Moodley Y
    Respir Res; 2021 Apr; 22(1):105. PubMed ID: 33836757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.